<code id='7FBD1D5D39'></code><style id='7FBD1D5D39'></style>
    • <acronym id='7FBD1D5D39'></acronym>
      <center id='7FBD1D5D39'><center id='7FBD1D5D39'><tfoot id='7FBD1D5D39'></tfoot></center><abbr id='7FBD1D5D39'><dir id='7FBD1D5D39'><tfoot id='7FBD1D5D39'></tfoot><noframes id='7FBD1D5D39'>

    • <optgroup id='7FBD1D5D39'><strike id='7FBD1D5D39'><sup id='7FBD1D5D39'></sup></strike><code id='7FBD1D5D39'></code></optgroup>
        1. <b id='7FBD1D5D39'><label id='7FBD1D5D39'><select id='7FBD1D5D39'><dt id='7FBD1D5D39'><span id='7FBD1D5D39'></span></dt></select></label></b><u id='7FBD1D5D39'></u>
          <i id='7FBD1D5D39'><strike id='7FBD1D5D39'><tt id='7FBD1D5D39'><pre id='7FBD1D5D39'></pre></tt></strike></i>

          Home / comprehensive / comprehensive

          comprehensive


          comprehensive

          author:knowledge    Page View:42487
          Adobe

          LONDON — GSK said Tuesday it would purchase the asthma-focused drug developer Aiolos Bio for $1 billion upfront, the latest in a string of pharma acquisitions that are bolstering hopes for the industry’s year ahead.

          The deal includes up to another $400 million in payments if certain milestones are met.

          advertisement

          Aiolos was launched just last year, based in both San Francisco and London. The company, which announced a $245 million Series A round in October, has been readying a Phase 2 trial of its candidate AIO-001 in adult asthma.

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In